Need for additional capital and continued losses
The company expects to continue incurring losses and may need to raise capital to fund operations and execute its plan.
- Materiality
- high
ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology biotechnology company focused on antibody drug conjugates (ADCs). Its marketed product, ZYNLONTA (loncastuximab tesirine-lpyl), is a CD19-directed ADC approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more prior systemic therapies, with approvals spanning the U.S. and conditional approvals in Europe, Canada and China. The company combines in-house R&D capabilities with outsourced manufacturing and third-party commercialization infrastructure, while building a pipeline that extends ADC technology into additional hematologic malignancies and solid tumors. Operations are headquartered in Lausanne, Switzerland, with a U.S. presence in New Jersey supporting development and commercialization.
−148,5 %
92,9 %
−175,3 %
+14,9 %
4.37
4.31
| % | |
|---|---|
| ZYNLONTA product sales (U.S.) | 80% Net product revenue from U.S. sales of ZYNLONTA to wholesalers for use in r/r DLBCL. |
| Ex-U.S. partnered commercialization (Greater China & Singapore) | 10% Licensed development and commercialization in China, Hong Kong, Macau, Taiwan and Singapore via Overland ADCT BioPharma, supplied by ADCT at manufacturing cost. |
| Clinical development programs (ZYNLONTA label expansion) | 5% Company-sponsored trials such as LOTIS-5 and LOTIS-7 aimed at moving ZYNLONTA into earlier lines and combinations. |
| Early-stage pipeline and platform R&D | 5% Discovery/IND-enabling and early clinical work leveraging the ADC platform, including solid-tumor programs such as ADCT-241 (PSMA-targeting). |
In the United States, ADC Therapeutics sells ZYNLONTA through wholesale distributors that resell to hospitals, infusion...
- U.S. oncology providers (academic and community)primary
Use ZYNLONTA for r/r DLBCL patients; adoption depends on clinical profile, pathway placement and reimbursement.
- U.S. channel intermediaries (wholesalers and distributors)primary
Purchase and distribute ZYNLONTA to provider sites; terms drive inventory levels, fees and gross-to-net adjustments.
- Payers and government reimbursement programssecondary
Determine net realized price through rebates, chargebacks, fees and policies such as discarded drug rebates.
- Ex-U.S. partner (Overland ADCT BioPharma)secondary
Develops, seeks regulatory approvals and commercializes in greater China and Singapore; ADCT supplies product at cost and may co-promote via option.
ADC Therapeutics is headquartered in Lausanne (Biopôle), Switzerland, with U.S. operations in New Jersey supporting...
- •Headquarters in Lausanne (Biopôle), Switzerland
- •U.S. operations in New Jersey supporting commercial and R&D activities
- •Direct commercialization focus in the United States for ZYNLONTA
- •Greater China & Singapore partnered via Overland ADCT BioPharma license/JV
- •Regulatory exposure spans FDA, European Commission, NMPA and Health Canada
- •Tariffs/trade policy changes can impact cross-border supply chain costs
The company’s near-term strategy centers on maximizing ZYNLONTA by expanding use beyond third-line DLBCL into earlier...
01
Confirm and expand ZYNLONTA in DLBCLmedium-term
Earlier-line and combination use increases addressable patients and supports durable approvals.
02
Broaden hematology indications beyond DLBCLmedium-term
Indolent lymphoma expansion can diversify demand while leveraging the same commercial channel.
03
Advance and partner the solid-tumor ADC portfoliolong-term
Solid tumors expand long-term optionality but may require partnerships to fund development and commercialization.
ADC Therapeutics’ business is highly dependent on ZYNLONTA, so any slowdown in adoption, competitive displacement (e.g...
HCR royalty purchase agreement reduces cash generation from ZYNLONTA
Cash retained from ZYNLONTA sales/licensing is reduced and the obligation can vary with sales milestones and change-of-control timing.
- Materiality
- high
Clinical trial timing and outcome uncertainty
Ongoing/planned trials may not complete on expected timelines or produce sufficient results to support approvals/label expansion.
- Materiality
- high
Product safety and adverse events
Undesirable side effects could reduce physician adoption, lead to warnings/restrictions, or increase post-marketing obligations.
- Materiality
- high
Tariffs and trade policy changes
Changes in tariffs/trade policies could increase cost of sales and operating expenses, impacting margins and cash burn.
- Materiality
- medium
Product revenues, net (gross-to-net adjustments)
Revenue, accounts receivable/contra-revenue reserves, period-to-period volatility
Discarded drug rebate estimation
Contra-revenue reserves and operating cash flow timing
Deferred royalty obligation (HCR) and accretion
Interest expense and carrying value of the royalty obligation
Whitehawk Therapeutics, Inc.
WHWK · Pharmaceutical Preparations
ALX ONCOLOGY HOLDINGS INC
ALXO · Pharmaceutical Preparations
ALX Oncology Holdings Inc is a clinical-stage biotechnology company developing immuno-oncology therapies for cancer, headquartered in South San Francisco, California.
Akari Therapeutics Plc
AKTX · Pharmaceutical Preparations
Akari Therapeutics Plc is a clinical-stage biotechnology company that has shifted its focus toward oncology, specifically next-generation antibody-drug…
Adicet Bio, Inc.
ACET · Pharmaceutical Preparations
Black Diamond Therapeutics, Inc.
BDTX · Biological Products, (No Diagnostic Substances)
Alector, Inc.
ALEC · Biological Products, (No Diagnostic Substances)
: 11/08/2026